On September 8, PHARMARON rose 3.19% in regular trading, trading at HKD 29.18 per share, with turnover of approximately HKD 85.07 million. The stock was buoyed by a confluence of positive catalysts including sustained institutional accumulation and robust industry fundamentals.
On the institutional front, Morgan Stanley raised its long position in PHARMARON H-shares to 7.15%, after purchasing approximately 2.765 million shares at an average price of HKD 29.62 on August 27. JPMorgan Chase increased its stake from 8.25% to 11.43% on August 26, while Citigroup lifted its holding from 4.49% to 5.46% over the same period. BOCOM International noted that the CXO segment posted the fastest growth among all pharmaceutical sub-sectors, with Hong Kong-listed and A-share CXO revenues rising 29.2% and 25.3% respectively in H1, underscoring elevated industry demand.
PHARMARON reported H1 revenue of RMB 7.595 billion, up 17.9% year-over-year, with new orders growing over 30% and CDMO new orders surging over 50%. Management subsequently raised full-year revenue growth guidance to 15%-20%. The company is scheduled to hold an extraordinary general meeting on September 10 to vote on a buyback authorization for up to 10% of issued H-shares. Additionally, the company completed a RMB 2.18 billion zero-coupon convertible bond issuance on September 2.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments